Annual Report

Overview

The report describes Biocon's FY22 transformation into a technology-enabled biopharmaceuticals group, with consolidated revenue of ₹83,967 million and a workforce of approximately 15,000. Sustainability highlights include entry into the DJSI Emerging Markets Index, an improved CDP rating of B, 54% group green-power share and 186,500 tCO2 carbon-footprint reduction. The report also details healthcare-access, COVID-care, education, waterbody rejuvenation and community infrastructure initiatives.

Document

Report type: Annual Report with Sustainability Disclosures
Class: Embedded
Scope: Full report
Fiscal year: 2021
Period: 1 April 2021 – 31 March 2022
Language: English
Pages
File size
Restatement: Disclosed

Standards

GRI
SASB
TCFD
ISSB
ESRS
Integrated Reporting Framework
GHG Protocol
EU Taxonomy
CDP

Ratings

GRI level
CDP score

Materiality

Assessment
Basis

Assurance

Statement included

Data Services

Turn sustainability reports into a dataset built for your research.

From bulk PDFs to structured indicators and machine-readable documents.

View services